Pancragen
Fat LossKhavinson pancreatic bioregulator / researchExperimental
Short peptide marketed for pancreatic islet bioregulator research. Not FDA-approved.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- —
- Last updated
- Aug 23, 2026
- Targets
- Pancreatic cells (proposed)
Overview
Short peptide marketed for pancreatic islet bioregulator research. Not FDA-approved.
Protocol
- Dosage Range
- Vendor research protocols only
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Science
Mechanism of Action
Claimed to support pancreatic protein synthesis in older literature.
Origin
Synthetic short peptide.
Targets
Pancreatic cells (proposed)
Studies
Benefits
Historical pancreatic-bioregulator category
Potential Side Effects
Side Effects
- Not characterized
References
- PMID 15587334External reference